1. 1-19 of 19
    1. Lilly CEO David Ricks Snags $17.2M Pay Package for 2018, a 9% Hike

      Lilly CEO David Ricks Snags $17.2M Pay Package for 2018, a 9% Hike

      by Eric Sagonowsky | Mar 13, 2019 11:16am Lilly CEO David Ricks made 189 times the company's median employee compensation in 2018, the drugmaker reported. (LillyPad) Eli Lilly CEO David Ricks, in his second year on the job, snared a pay package larger than those of a few of his Big Pharma peers. And it's not far shy of the amount his predecessor, John Lechleiter, hauled in for his final—and eighth—year as Lilly chief...

      Read Full Article
    2. Does Bristol-Myers Have a Plan B if Activists Scuttle its Celgene Buy?

      Does Bristol-Myers Have a Plan B if Activists Scuttle its Celgene Buy?

      What’s Bristol-Myers Squibb’s Plan B if its Celgene deal falls through? BMS won’t say whether it has one at all. And the company may be more likely to need a backup plan than some industry-watchers think. As Wolfe Research’s Tim Anderson pointed out in a note to clients, the company has so far skirted questions about how it would proceed without the $74 billion takeout, saying only that “their focus is on getting the Celgene deal done.” “They gave no insights on the path forward under this alternative scenario,” Anderson wrote, noting that if the deal ...

      Read Full Article
    3. AstraZeneca Pays CEO Soriot Nearly $15M After 2018's Return to Growth. Will Investors Push Back?

      AstraZeneca Pays CEO Soriot Nearly $15M After 2018's Return to Growth. Will Investors Push Back?

      AstraZeneca CEO Pascal Soriot earned £11.36 million in total pay last year, a 9% increase over 2017. (AstraZeneca) In the past, AstraZeneca's investors have hit out at the company for executive compensation they deemed over-the-top. And they may have something to say about CEO Pascal Soriot's £11.36 million ($14.93 million) in total pay last year, a 9% jump from 2017...

      Read Full Article
    4. Now that Ironwood's Spinning off R&D, Activist Alex Denner is Easing Up

      Now that Ironwood's Spinning off R&D, Activist Alex Denner is Easing Up

      Activist investor Sarissa Capital said it would support Ironwood's board in light of its recently announced move to spin off most of its R&D unit. (Pixabay) Ironwood’s activist investor likes what it’s seen recently from the drugmaker—so much so that it held off on pushing for a spot on the company's board....

      Read Full Article
    5. Despite 34% Cut, AstraZeneca Shareholders Still Don't Like CEO Soriot's £9.4M Pay

      Despite 34% Cut, AstraZeneca Shareholders Still Don't Like CEO Soriot's £9.4M Pay

      AstraZeneca shareholders revolted over executive pay again this year, with 35% having voted against it, including the £9.4 million package for CEO Pascal Soriot. (AstraZeneca) AstraZeneca has made some headway with investors persistently provoked by its executive pay—but not much...

      Read Full Article
    6. China's Sinovac Biotech Halts Hep A Vaccine Production Amid Boardroom Drama Over Company

      China's Sinovac Biotech Halts Hep A Vaccine Production Amid Boardroom Drama Over Company

      Beijing-based Sinovac Biotech, whose CEO is locked in a battle for control of the company, has suspended production of its hepatitis A vaccine and destroyed supplies on hand. A yearlong internal power struggle for control of Chinese vaccine maker Sinovac Biotech has spilled from the boardroom to the production floor, forcing the company to suspend manufacturing of its hepatitis A vaccine...

      Read Full Article
    7. Ready to Rumble, Ironwood? Activist Investor Alex Denner Suits up for Board-Seat Bid

      Ready to Rumble, Ironwood? Activist Investor Alex Denner Suits up for Board-Seat Bid

      Activist investor Alex Denner is back at it in biopharma. Just a few months after playing a pivotal role in Sanofi’s Bioverativ acquisition, he has set his sights on Ironwood Pharmaceuticals. The Massachusetts drugmaker on Monday said it had received word from Denner’s Sarissa Capital Management, which held 1.92 million Ironwood shares at the end of 2017, that it intended to nominate Denner for Ironwood’s board...

      Read Full Article
    8. J&J's Duato, Peterson Nab Hefty Retention Bonuses as CEO Gorsky's Pay Hits $29M

      J&J's Duato, Peterson Nab Hefty Retention Bonuses as CEO Gorsky's Pay Hits $29M

      Thanks to target beating financials and more, J&J pharma chief Joaquin Duato racked up $19 million in reported pay for 2017. (Johnson & Johnson) That Johnson & Johnson CEO Alex Gorsky got a bit of a raise in 2017 isn't all that surprising. After all, his compensation package has increased bit by bit over the past several years. More notable are the boosts enjoyed by two of Gorsky's team members...

      Read Full Article
    9. Bristol-Myers CEO Giovanni Caforio Nets $18.7M in 2017 Pay, a 10% Raise

      Bristol-Myers CEO Giovanni Caforio Nets $18.7M in 2017 Pay, a 10% Raise

      As Bristol-Myers Squibb presses ahead in oncology and after a big finish in the fourth quarter, CEO Giovanni Caforio is taking home a 10% pay raise for 2017 to $18.7 million. His stepped-up compensation followed a year in which Bristol-Myers exceeded the CEO's overall revenue target—and beat individual sales targets for a list of key drugs...

      Read Full Article
    10. Investors in AbbVie, Lilly, Amgen and More Set to Vote on Executive Pay, drug pricing

      Investors in AbbVie, Lilly, Amgen and More Set to Vote on Executive Pay, drug pricing

      Several drugmakers resisted shareholder resolutions into the relationship between executive pay and drug prices. (Pixabay) Despite resistance from top pharma companies, shareholders are set to vote this spring on resolutions seeking more information about potential links between executive pay and rising drug prices...

      Read Full Article
    11. The top 15 highest-Paid Biopharma Executives

      The top 15 highest-Paid Biopharma Executives

      Tracking executive pay follows a familiar pattern: Collect compensation disclosures, read said documents as they pile up, and when the usual suspects have all filed their annual reports and proxy statements, put the numbers into a spreadsheet and sort descending. The first documents surface as early as January and trickle into May. European Big Pharma comes first; a certain few U.S. drugmakers file their proxies much later than the rest...

      Read Full Article
    12. How Can Pharmas Avoid Scandal? Don't Hire Rule-Breakers, Novartis CEO Says

      How Can Pharmas Avoid Scandal? Don't Hire Rule-Breakers, Novartis CEO Says

      Novartis chief Joe Jimenez knows a thing or two about dealing with scandals. And his advice to other execs on how to avoid them? It all starts with recruiting the right staff. The recruitment process is the time to filter out job candidates who will perform no matter the cost--as opposed to those who want to perform, but also want to follow the rules, Jimenez said at a recent leadership symposium. And that’s something he says the Swiss pharma giant has learned to do ...

      Read Full Article
      Mentions: Leadership SEC CEO
    13. Valeant Under Criminal Investigation Over Philidor Ties

      Valeant Under Criminal Investigation Over Philidor Ties

      With Valeant’s management assuring investors that the company is well on its way to a turnaround, the drugmaker’s problems aren’t supposed to be growing larger. But now, Valeant is facing what could be its most serious investigation yet. Federal prosecutors are probing the Canadian drugmaker’s relationship with specialty pharmacy Philidor, The Wall Street Journal ’s sources say...

      Read Full Article
    14. 'Same old Valeant'? Ackman's Presence at Quiet-Period Investor Meeting Draws Fire

      'Same old Valeant'? Ackman's Presence at Quiet-Period Investor Meeting Draws Fire

      It’s not uncommon for fund managers to hold small dinners to meet with investors and discuss their investment bets. But for a board member of a company to attend one during that company’s quiet period? That’s a recent Valeant move that’s raising some eyebrows. In late June, Valeant director Bill Ackman attended a Bank of America event--billed as “Valeant: a Bull/Bear dinner”--in New York City, sources tell Reuters...

      Read Full Article
    1-19 of 19
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content